Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.

Saved in:
Bibliographic Details
Title: Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.
Authors: Coleman N; The University of Texas MD Anderson Cancer Center , Houston, Texas.; Trinity St. James's Cancer Institute, St. James's Hospital, Dublin, Ireland.; Trinity College Dublin, Dublin, Ireland., Wei Z; Trinity College Dublin, Dublin, Ireland., Iafrate AJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Gray RJ; Trinity College Dublin, Dublin, Ireland., Wang V; Trinity College Dublin, Dublin, Ireland., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Patton DR; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland., Williams PM; Frederick National Laboratory for Cancer Research , Frederick, Maryland., Hamilton SR; City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, California., Takebe N; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; University of Oklahoma College of Medicine, Oklahoma City, Oklahoma., Williams T; Saint Luke's Cancer Institute, Boise, Idaho., Croley JJ; Saint Joseph Hospital , Lexington, Kentucky., Onitilo AA; Marshfield Medical Center, Weston, Wisconsin., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Cheng J; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Karlovich C; Frederick National Laboratory for Cancer Research , Frederick, Maryland., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas., Harris L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., O'Dwyer PJ; University of Pennsylvania , Philadelphia, Pennsylvania., Hong DS; The University of Texas MD Anderson Cancer Center , Houston, Texas., Chen AP; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Apr 01; Vol. 32 (7), pp. 1224-1233.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-1247